[go: up one dir, main page]

WO2005007116A3 - Systemes de cellules presentant l'antigene artificielles - Google Patents

Systemes de cellules presentant l'antigene artificielles Download PDF

Info

Publication number
WO2005007116A3
WO2005007116A3 PCT/US2004/022919 US2004022919W WO2005007116A3 WO 2005007116 A3 WO2005007116 A3 WO 2005007116A3 US 2004022919 W US2004022919 W US 2004022919W WO 2005007116 A3 WO2005007116 A3 WO 2005007116A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen presenting
presenting cell
artificial antigen
cell devices
aapc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/022919
Other languages
English (en)
Other versions
WO2005007116A2 (fr
Inventor
Michael L Gruenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VALEOCYTE THERAPIES LLC
Original Assignee
VALEOCYTE THERAPIES LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VALEOCYTE THERAPIES LLC filed Critical VALEOCYTE THERAPIES LLC
Publication of WO2005007116A2 publication Critical patent/WO2005007116A2/fr
Anticipated expiration legal-status Critical
Publication of WO2005007116A3 publication Critical patent/WO2005007116A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention a trait à des procédés et à des compositions concernant un système de cellules présentant l'antigène artificielles (système « aAPC »). Les systèmes aAPC selon l'invention renferment un agent de liaison qui améliore considérablement l'efficacité des agonistes liés, de façon à stimuler et à élargir une population de lymphocytes T qui sont de grands producteurs de cytokines pro-inflammatoires telles que IFN-η. De telles cellules sont des compositions utiles pour des protocoles d'immunothérapie adoptive.
PCT/US2004/022919 2003-07-18 2004-07-16 Systemes de cellules presentant l'antigene artificielles Ceased WO2005007116A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48864103P 2003-07-18 2003-07-18
US60/488,641 2003-07-18

Publications (2)

Publication Number Publication Date
WO2005007116A2 WO2005007116A2 (fr) 2005-01-27
WO2005007116A3 true WO2005007116A3 (fr) 2006-12-14

Family

ID=34079444

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/022919 Ceased WO2005007116A2 (fr) 2003-07-18 2004-07-16 Systemes de cellules presentant l'antigene artificielles

Country Status (1)

Country Link
WO (1) WO2005007116A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1736482A1 (fr) * 2005-06-20 2006-12-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Ligand recombinant trimeric de 4-1BB
EP2025747A1 (fr) * 2007-08-14 2009-02-18 TumorTec GmbH Procédé d'amplification in vitro de lymphocytes T-régulateurs
CN104204194B (zh) * 2011-12-22 2018-08-03 财团法人牧岩生命工学研究所 生产自然杀伤细胞的方法、由该方法生产的自然杀伤细胞以及包含该自然杀伤细胞的用于治疗癌症和感染性疾病的组合物
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
CN110662834B (zh) 2017-05-26 2023-09-12 Gc细胞治疗 使用转化的t细胞培养自然杀伤细胞的方法
EP3892721A4 (fr) 2018-11-14 2022-08-31 GC Cell Corporation Procédé de culture de cellules tueuses naturelles dérivées de sang de cordon ombilical au moyen de lymphocytes t transformés

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029436A1 (fr) * 1993-06-04 1994-12-22 The United States Of America Represented By The Secretary Of The Navy Procedes de stimulation selective de la proliferation des lymphocytes t
WO1997005239A1 (fr) * 1995-07-25 1997-02-13 Celltherapy, Inc. Immunotherapie par cellules autologues: compositions cellulaires , methodes et application au traitement d'une maladie humaine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029436A1 (fr) * 1993-06-04 1994-12-22 The United States Of America Represented By The Secretary Of The Navy Procedes de stimulation selective de la proliferation des lymphocytes t
WO1997005239A1 (fr) * 1995-07-25 1997-02-13 Celltherapy, Inc. Immunotherapie par cellules autologues: compositions cellulaires , methodes et application au traitement d'une maladie humaine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCHAFER P.H. ET AL.: "P38alpha mitogen-activated protein kinase is activated by CD28-mediated signaling and is required for IL-4 production by human CD4+Cd45RO+ T cells and Th2 effector cells", J. OF IMMUNOLOGY, vol. 162, 1999, pages 7110 - 7119, XP002966702 *
SWANSON M.A. ET AL.: "IFN-gamma Production by Th1 Cells Generated from Naive CD4+ T Cells Exposed to Norepinephrine", JOURNAL OF IMMUNOLOGY, vol. 166, 2001, pages 232 - 240, XP003004913 *

Also Published As

Publication number Publication date
WO2005007116A2 (fr) 2005-01-27

Similar Documents

Publication Publication Date Title
EP1266959A3 (fr) Anlage und verfahren zur gewinnen von zellen
WO2005037233A3 (fr) Vaccins epha2 a base de listeria
AU2003209259A1 (en) Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
MXPA05013973A (es) Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.
WO2001094944A3 (fr) Cellules presentatrices d'antigene artificiel et leurs methodes d'utilisation
EP1644136B8 (fr) Dispositif electrochimique a base de particules seches et son procede de fabrication
WO2007067782A3 (fr) Compositions et procédés permettant d'induire l'activation de cellules dendritiques monocytiques immatures
HUE038833T2 (hu) Antigénspecifikus T-sejtek létrehozása
TW200517126A (en) Mesothelioma therapeutic agent
SI1648507T1 (sl) Metode in sestavki za povečanje učinkovitosti terapevtskih protiteles z uporabo potenciranja spojin nk celice
PL372098A1 (en) Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
WO2006095330A3 (fr) Methodes et preparations de cellules immunogenes destinees a traiter des maladies associees a un antigene
WO2005000348A3 (fr) Matieres et procedes concernant la modulation de la reponse des lymphocytes t a un antigene soluble
DK1553832T3 (da) Præparater og fremgangsmåder til celleseparering
WO2006047515A3 (fr) Cellules dendritiques chargees de corps cellulaires de melanome de choc thermique
WO2005007116A3 (fr) Systemes de cellules presentant l'antigene artificielles
AU2003251898A1 (en) Device and methods for isolating target cells
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
WO2006090291A3 (fr) Procede
WO2003063801A3 (fr) Traitement de cellules tumorales destinees a l'immunotherapie du cancer
WO2008025992A3 (fr) Méthodes de développement de populations de lymphocytes t
AU2003287521A1 (en) Pluripotent cells from monocytes, and methods of making and using pluripotent cells
MXPA05009527A (es) Implante labial y metodo para la insercion.
WO2005056763A3 (fr) Procede et formulation pour l'amelioration de la viabilite de cellules et de tissu stockes
AU2003254879A1 (en) Method of transferring selected molecule into target cells, method of cell-fusing target cells and plasma exposure device to be used in these methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase